Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 4/20 | 0.40 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807768 | 0.87 | KDM4E (0.47) | KDM4EL3MBTL1MEN1MAPK1KMT2A | |
| SCHEMBL2805108 | 0.78 | RAB9A (0.43) | KDM4EL3MBTL1MEN1MAPK1KMT2A | |
| SCHEMBL2807549 | 0.77 | MAPT (0.41) | KDM4EL3MBTL1MEN1KMT2APOLB | |
| SCHEMBL30336602 | 0.76 | KDM4E (0.59) | KDM4EL3MBTL1MEN1MAPK1KMT2A | |
| SCHEMBL30345053 | 0.76 | KDM4E (0.59) | KDM4EL3MBTL1MEN1MAPK1KMT2A | |
| SCHEMBL25717389 | 0.76 | KDM4E (0.59) | KDM4EL3MBTL1MEN1MAPK1KMT2A | |
| SCHEMBL23196070 | 0.74 | POLB (0.50) | KDM4EL3MBTL1MEN1MAPK1KMT2A | |
| SCHEMBL31022692 | 0.73 | KDM4E (0.51) | KDM4EL3MBTL1MEN1MAPK1KMT2A | |
| SCHEMBL25242780 | 0.73 | KDM4E (0.51) | KDM4EL3MBTL1MEN1MAPK1KMT2A | |
| SCHEMBL16474108 | 0.72 | MAPT (0.46) | KDM4EL3MBTL1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | disclosed |
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | disclosed |
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2014-01-09 | — | — | US | disclosed |
| US-8592446-B2 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2013-11-26 | — | — | US | disclosed |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-09-23 | — | — | US | disclosed |
| EP-2170464-A2 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008152068-A2 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152068-A2 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | NOSCIRA, S.A. (ES) | 2008-12-18 | — | — | WO | disclosed |
| EP-2002863-A1 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2008-12-17 | — | — | EP | disclosed |
| EP-2002863-A1 | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | NOSCIRA, S.A. (ES) | 2008-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011835-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | HTT, PARK7, ATXN10 | KDM4E 1412/4885L3MBTL1 2710/4885MEN1 477/4885 |
| US-20100240692-A1 | [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES | HTT, ATXN10, PSEN1 | KDM4E 1922/4885L3MBTL1 3762/4885MEN1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.